vs
CIVISTA BANCSHARES, INC.（CIVB）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
CIVISTA BANCSHARES, INC.的季度营收约是REGENXBIO Inc.的1.6倍（$47.3M vs $30.3M），CIVISTA BANCSHARES, INC.净利率更高（31.7% vs -221.3%，领先253.1%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 11.3%）
Civista Bancshares Inc.是一家总部位于美国的银行控股公司，主要在中西部地区运营，面向零售客户、本地中小企业及社区群体提供个人与商业银行服务，包括存款账户、各类贷款产品及财富管理解决方案。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CIVB vs RGNX — 直观对比
营收规模更大
CIVB
是对方的1.6倍
$30.3M
净利率更高
CIVB
高出253.1%
-221.3%
两年增速更快
RGNX
近两年复合增速
11.3%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $47.3M | $30.3M |
| 净利润 | $15.0M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 31.7% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 47.4% | -31.2% |
| 每股收益（稀释后） | $0.72 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CIVBRGNX
| Q1 26 | $47.3M | — | ||
| Q4 25 | $46.3M | $30.3M | ||
| Q3 25 | $44.2M | $29.7M | ||
| Q2 25 | $41.4M | $21.4M | ||
| Q1 25 | $40.6M | $89.0M | ||
| Q4 24 | $40.4M | $21.2M | ||
| Q3 24 | $39.3M | $24.2M | ||
| Q2 24 | $38.1M | $22.3M |
净利润CIVBRGNX
| Q1 26 | $15.0M | — | ||
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $12.8M | $-61.9M | ||
| Q2 25 | $11.0M | $-70.9M | ||
| Q1 25 | $10.2M | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $8.4M | $-59.6M | ||
| Q2 24 | $7.1M | $-53.0M |
毛利率CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 31.8% | -190.0% | ||
| Q3 25 | 35.4% | -176.3% | ||
| Q2 25 | 31.1% | -296.3% | ||
| Q1 25 | 29.4% | 13.6% | ||
| Q4 24 | 28.2% | -242.1% | ||
| Q3 24 | 25.2% | -256.6% | ||
| Q2 24 | 21.2% | -251.3% |
净利率CIVBRGNX
| Q1 26 | 31.7% | — | ||
| Q4 25 | — | -221.3% | ||
| Q3 25 | 28.9% | -208.3% | ||
| Q2 25 | 26.6% | -331.8% | ||
| Q1 25 | 25.0% | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 21.3% | -246.3% | ||
| Q2 24 | 18.5% | -237.7% |
每股收益（稀释后）CIVBRGNX
| Q1 26 | $0.72 | — | ||
| Q4 25 | $0.59 | $-1.30 | ||
| Q3 25 | $0.68 | $-1.20 | ||
| Q2 25 | $0.71 | $-1.38 | ||
| Q1 25 | $0.66 | $0.12 | ||
| Q4 24 | $0.62 | $-0.99 | ||
| Q3 24 | $0.53 | $-1.17 | ||
| Q2 24 | $0.45 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $553.9M | $102.7M |
| 总资产 | $4.3B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M |
股东权益CIVBRGNX
| Q1 26 | $553.9M | — | ||
| Q4 25 | $543.5M | $102.7M | ||
| Q3 25 | $499.0M | $161.5M | ||
| Q2 25 | $404.1M | $213.7M | ||
| Q1 25 | $397.4M | $274.2M | ||
| Q4 24 | $388.5M | $259.7M | ||
| Q3 24 | $394.4M | $301.4M | ||
| Q2 24 | $373.8M | $348.3M |
总资产CIVBRGNX
| Q1 26 | $4.3B | — | ||
| Q4 25 | $4.3B | $453.0M | ||
| Q3 25 | $4.1B | $525.2M | ||
| Q2 25 | $4.2B | $581.0M | ||
| Q1 25 | $4.1B | $490.9M | ||
| Q4 24 | $4.1B | $466.0M | ||
| Q3 24 | $4.1B | $519.1M | ||
| Q2 24 | $4.0B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $43.3M | $-52.3M | ||
| Q3 25 | $19.0M | $-56.0M | ||
| Q2 25 | $11.1M | $-49.3M | ||
| Q1 25 | $3.6M | $33.6M | ||
| Q4 24 | $48.2M | $-31.6M | ||
| Q3 24 | $12.9M | $-40.5M | ||
| Q2 24 | $12.2M | $-45.5M |
自由现金流CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | $42.1M | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $3.5M | $32.6M | ||
| Q4 24 | $44.1M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M |
自由现金流率CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 90.9% | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | 8.5% | 36.6% | ||
| Q4 24 | 109.1% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% |
资本支出强度CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | 2.5% | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | 0.4% | 1.2% | ||
| Q4 24 | 10.4% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% |
现金转化率CIVBRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 1.49× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 0.36× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | — | ||
| Q2 24 | 1.73× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CIVB
| Net Interest Income | $37.8M | 80% |
| Noninterest Income | $9.4M | 20% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
